Sentences with phrase «cell disease challenged»

Not exact matches

Venter reiterated this sentiment: «Using the combined power of our core areas of expertise — genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical / scientific and societal challenges — aging and aging related diseases,» he said in a statement.

«Using the combined power of our core areas of expertise — genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical / scientific and societal challenges — aging and aging related diseases,» said Dr. Venter.

«Mechanistic finding may help develop treatment for Ice Bucket Challenge disease: Study blames a fault in the cell's machine that cuts and pastes genetic instructions for a deadly motor neuron disease.»

The mini-brain lasts about a month and it could be used to study a range of challenges in neuroscience including transplanting nerve cells that could help treat Parkinson's disease and studies on how adult nerve stem cells develop.

In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases — and eventually in treating them.

It's been challenging to zoom in on the population of T cells driving the disease in part because when psoriasis is active, lesions are flooded with diverse T cells.

But studying how the cells of complex tissues like the mammary gland self - organize, make decisions as groups, and break down in disease has been a challenge to researchers.

A major challenge has been to find a way to better understand the way the disease affects human nerve cells.

Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that cancer cell biologists are furiously pursuing.

In a paper published in Scientific Reports, the HDNetDB team outlines the challenges facing those investigating Huntington's disease, explains how HDNetDB works and illustrates its effectiveness by discovering potential drug targets, which might help to prevent the neuronal cell death observed in Huntington's disease.

«Identifying gene variants that are general risk factors for neurological and psychiatric disease is important, but understanding exactly which cell types in the developing brain are compromised and what the consequences are is still extremely challenging,» Pollen added.

The findings challenge the long - held theory that leukemia cells simply outperform healthy cells by living longer and suggest that targeting this «death factor» may be a viable way of combating the disease.

We've found innovative ways to treat challenging diseases (the U.S. Food and Drug Administration's approval of CAR - T cell therapy for certain blood cancers is our No. 8 story).

As expected, xenogeneic graft versus host disease (GVHD), assessed clinically by dermatitis and hair loss, was observed in mice receiving cells treated with both R5 - ZFNs and X4 - ZFNs in the absence of HIV challenge.

However, despite its marked promise for disease modeling, development of novel therapies, and regenerative medicine, stem cell derived organoid technology faces many remaining challenges.

«Using the combined power of our core areas of expertise — genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical / scientific and societal challenges — aging and aging related diseases,» said Dr. Venter.

But editing the DNA of cells in a petri dish — or even curing a mouse of a disease — is one thing; making the hot new technology work in humans is a whole other challenge.

A major challenge that will be addressed in the second phase of LINCS is to optimize the combinations of cell types, perturbations and measurements of cellular responses to address a wider range of basic biological and disease - related problems than was possible in the program's initial pilot stage, said Alan Michelson, M.D., Ph.D., senior investigator, Laboratory of Developmental Systems Biology, NHLBI, and co-chair of the NIH LINCS Project Implementation Team.

New therapies for disorders like Huntington's disease are on the way, but getting the drugs to enter brain cells can be a major challenge.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

«By getting stuff into the cells, you can understand the disease and hence design therapies,» says Armon Sharei, lead author of a recent article on a new and vector - free microfluidic transfection technique, addressing the transfection challenge.